best cbd oils in united states

Cannabinoids CBC and CBG exhibit anti-tumour properties on cancer cells

The test have been carried out by Cannabics Pharmaceuticals at the company’s High Through-put Screening (HTS) facility in Israel. The tests have shown that the cannabinoids CBC (Cannabichromene) and CBG (Cannabigerol) both exhibit anti-tumour properties after being tested on human Gastrointestinal Cancer Cells.

CBC and CBG

CBC is an additional non-psychoactive cannabinoid and is one of the naturally occurring phyto-cannabinoids, bearing a host of potential positive therapeutic qualities and may promote antimicrobial, anti‐inflammatory, analgesic, and neurogenesis activity. It is particularly found in younger cannabis plants, albeit in small quantities.

In these tests, the HTS platform was utilised to screen the necrotic effects of a variety of cannabinoids on human gastrointestinal cancer cells, in addition to other cancer types previously tested.

CBC and CBG were both shown to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids.

Dr Yaakov Waksman, the company’s head of cannabidiol research, said: “My working assumption is that these results show that a correlation may exist between a cannabinoid’s Topological Polar Surface Area (TPSA) value and its ability to induce anti-tumour activity, diminishing cancer cell’s viability rates.

“CBC and CBG, as neutral cannabinoids, were both found to have a TPSA value which allows the cannabinoid molecule to penetrate a cancer cell’s membrane, whereas their acidic form (CBCA and CBGA) – do not. This could explain the difference in anti-tumour activity rates demonstrated”.

Dr Eyal Ballan, CTO and Co-Founder, added: “Gastrointestinal cancers are amongst the leading and most wide-spread causes of cancer-related deaths worldwide. We are intrigued by the results we have obtained in the lab, and our aim is to consider placing an emphasis on this organ system, and to further explore the differential anti-tumour properties of cannabinoids.

“We believe that these preliminary results vindicate our vision; which is to bring personalisation into cannabinoid-based cancer treatments.”

How to Incorporate C BD Into Your Chiropractic Practice

As a chiropractor, it’s important to keep up to date with industry trends to ensure you are offering patients a comprehensive approach to treatment. Over the past few years, topical cannabidiol (CBD) products have grown in popularity, especially in the chiropractic market1as they have been linked to alternative relief for sore muscles and joints. With so many hemp-derived CBD products on the market, it can be difficult to choose the right ones for your patients and practice. 

Let’s dive into the steps you can take to begin incorporating CBD products into your practice. 

Legalization & CBD

When the  Agricultural Improvement Act of 2018 AKA 2018 Farm Bill was passed, it removed “hemp” from the definition of “marijuana”, so long as the THC concentration does not exceed 0.3 percent.Despite the fact that on a federal level, hemp crop regulation is in the hands of the U.S. Department of Agriculture, the legislation preserved the FDA’s responsibility over such products.3 For chiropractors looking to incorporate CBD products into their practice, it is crucial to understand the legal status of CBD in your state of practice so that you are acting in line with the law.

Do I Need a License to Sell CBD at My Practice? 

The 2018 Farm Bill recognizes the federal legalization of hemp-derived CBD in the United States—but not statewide regulations about CBD, which vary by state. Before integrating CBD into your practice, research your state’s laws regarding hemp-derived CBD.

In terms of a license, your chiropractic practice should have a business license, as well as a seller’s permit if you intend to sell any products to patients in your practice.4 This type of permit is handled on the state level, so refer to your local or state government for guidance on obtaining a seller’s permit for your chiropractic practice. 

At MeyerDC, we sell topical, hemp-derived CBD products to chiropractors in the following states: Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Michigan, Nevada, Ohio, Oregon, South Carolina, Tennessee, Wisconsin, and Washington. This is changing frequently due to state regulations on CBD, so check individual products for their availability in your state. 

4 Things to Know About the FDA’s C BD Guidance

When 2019 began, it was expected to be an incredibly “green” year for the cannabis industry. Canada had just commenced recreational weed sales in October 2018; higher-margin derivative products were expected to hit dispensary shelves in Canada soon thereafter; and President Trump had just signed the farm bill into law, thereby legalizing the industrial production of hemp and hemp-derived cannabidiol (CBD).

Arguably, the greatest excitement surrounded CBD, the nonpsychoactive cannabinoid that’s best known for its perceived medical benefits. Since CBD doesn’t get users high, there’s a considerably broader patient pool for infused products than anything marijuana related. And it also doesn’t hurt that the U.S. population is considerably larger than Canada, providing a juicier opportunity for the CBD industry.

Four vials of cannabinoid-rich liquid lined up on a counter.

IMAGE SOURCE: GETTY IMAGES.

Moreover, with President Trump signing the farm bill into law, it allowed general stores, such as pharmacies and grocers, the opportunity to carry hemp-derived CBD products. In other words, no longer are CBD products carried only in cannabis dispensaries. This more encompassing retail presence should provide a boost to industry sales.

According to the Brightfield Group, U.S. CBD product sales are expected to increase from around a pedestrian $600 million in 2018 to $23.7 billion by 2023. For those of you keeping score at home, this is, indeed, a compound annual growth rate of more than 100% per year over a five-year stretch. This makes CBD a much faster-growing niche than cannabis as a whole.

The FDA lays the hammer down on CBD

And yet, this rapidly growing niche is clouded in worry following a Nov. 25 consumer update from the U.S. Food and Drug Administration (FDA). To quickly summarize the consumer update, the FDA:

  • Noted that CBD has the potential to harm consumers.
  • Pointed out that CBD has the potential to cause side effects that might not immediately be noticed by consumers.
  • Admitted that there are numerous important aspects about CBD that the agency doesn’t know.
A lab researcher in a white coat closely examining a beaker filled with cannabinoid-rich liquid.

IMAGE SOURCE: GW PHARMACEUTICALS.

In particular, the FDA alluded to the only cannabis-derived drug, GW Pharmaceuticals‘ (NASDAQ:GWPH) Epidiolex, as evidence of these bullet points. Despite GW Pharmaceuticals’ lead drug being approved as a treatment for two rare forms of childhood-onset epilepsy in June 2018, Epidiolex was also shown to cause liver injury during clinical studies in some patients. Again, this risk didn’t outweigh the benefits GW Pharmaceuticals’ drug provided in terms of reducing seizure frequency from baseline, but it demonstrates in the eyes of the FDA that CBD doesn’t have a clean bill of health.

This FDA consumer update comes as the agency has been reviewing the compound as an additive to food, beverages, and dietary supplements. The FDA’s findings, based on the update, suggest that the agency is not going to grant companies the ability to add CBD to food, beverages, or dietary supplements at this time. And, as you can imagine, this news wasn’t taken well by Wall Street and investors.

Four things you should know about the FDA’s consumer update on CBD

However, it’s important for investors to understand that this FDA update isn’t as bad as it initially sounds. Here are four important takeaways from the FDA’s CBD guidelines.

1. This move had been telegraphed for months

For starters, the FDA’s consumer update that was critical of CBD’s safety could be seen coming months in advance. Remember, the agency never said it would release concrete guidelines by late summer or early fall. Instead, it only promised to provide an update on the progress it was making in reviewing data and testimony, which it has now done.

Additionally, the FDA hasn’t been shy about cracking down on misleading health claims when it comes to CBD. In July, Curaleaf Holdings (OTC:CURLF), the largest multistate operator in the U.S. by market cap, wound up receiving a warning letter regarding unsubstantiated claims for a variety of CBD products. Even though Curaleaf was quick to respond to these deficiencies, it still wound up costing the company a potentially lucrative distribution deal with CVS Health.

A researcher in a white lab coat making notes on a clipboard in the middle of a hemp farm.

What Are the Benefits of CBD?

More than 60 percent of CBD users were taking it for anxiety, according to a survey of 5,000 people. Does it help?

By Dawn MacKeen

The CBD industry is flourishing, conservatively projected to hit $16 billion in the United States by 2025. Already, the plant extract is being added to cheeseburgers, toothpicks and breath sprays. More than 60 percent of CBD users have taken it for anxiety, according to a survey of 5,000 people, conducted by the Brightfield Group, a cannabis market research firm.Chronic pain, insomnia and depression follow behind. Kim Kardashian West, for example, turned to the product when “freaking out” over the birth of her fourth baby. The professional golfer Bubba Watson drifts off to sleep with it. And Martha Stewart’s French bulldog partakes, too.


Cannabidiol, or CBD,is the lesser-known child of the cannabis sativaplant; its more famous sibling, tetrahydrocannabinol, or THC, is the active ingredient in pot that catapults users’ “high.” With roots in Central Asia, the plant is believed to have been first used medicinally — or for rituals — around 750 B.C., though there are other estimates too.

Cannabidiol and THC are just two of the plant’s more than 100 cannabinoids. THC is psychoactive, and CBD may or may not be, which is a matter of debate. THC can increase anxiety; it is not clear what effect CBD is having, if any, in reducing it. THC can lead to addiction and cravings; CBD is being studied to help those in recovery.

Cannabis containing 0.3 percent or less of THC is hemp. Although last year’s Farm Bill legalized hemp under federal law, it also preserved the Food and Drug Administration’s oversight of products derived from cannabis.


CBD is advertised as providing relief for anxiety, depression and post-traumatic stress disorder. It is also marketed to promote sleep. Part of CBD’s popularity is that it purports to be “nonpsychoactive,” and that consumers can reap health benefits from the plant without the high (or the midnight pizza munchies).

Just as hemp seedlings are sprouting up across the United States, so is the marketing. From oils and nasal sprays to lollipops and suppositories, it seems no place is too sacred for CBD. “It’s the monster that has taken over the room,” Dr. Brad Ingram, an associate professor of pediatrics at the University of Mississippi Medical Center, said about all the wild uses for CBD now. He is leading a clinical trial into administering CBD to children and teenagers with drug-resistant epilepsy.


What are the main medical benefits of CBD oil?

The legalization of marijuana has led to a deeper analysis and understanding of its components as well as how they can affect the user. CBD or cannabidiol is part of the over 100 chemical compounds referred to as cannabinoids. The other compound in marijuana is tetrahydrocannabinol (THC) and it is psychoactive, a feature that gives you a high feeling. CBD is not psychoactive hence its increasing popularity for health use. It is a quality natural remedy for relieving pain among other health benefits without the negative psychological effects associated with THC. Below are the medical benefits of CBD oil and later on, we’ll highlight the potential side effects.

Pain-relieving benefits of CBD Oil

CBD oil is used to help relieve pain for a healthier and quality lifestyle. When you use CBD oil, your body naturally releases endocannabinoids that act as cannabinoid receptors. CBD interacts with neurotransmitters, therefore, decreasing inflammation and easing chronic pain. According to studies, CBD oil can be used together with THC to address rheumatoid arthritis and multiple sclerosis, conditions that may significantly affect your life. When treating multiple sclerosis, CBD oil also reduces muscle spasms and improves your walking due to reduced pain.

Helps manage anxiety and relieve depression

Anxiety and depression are all symptoms of mismanaged stress and they may have adverse psychological disorders due to the affected mental function. According to research by the World Health Organization, depression is the number one cause of mental disability and anxiety comes in sixth. People who are depressed and experience anxiety have side effects like insomnia, sexual dysfunction, drowsiness, agitation, and headaches. To improve the quality of life, CBD oil is used alongside other carrier oils to manage anxiety and it has shown promising results in treating depression naturally. CBD oil also improves cognitive function, therefore, helping one speak comfortably in public. It is an effective treatment option for kids diagnosed with post-traumatic stress disorder as it also helps with insomnia. Studies show that CBD oil has anti-depressant effects that trigger the production of serotonin that controls your social behaviour and mood.

Scroll to top